4.7 Article

Adjuvant Host-Directed Therapy with Types 3 and 5 but Not Type 4 Phosphodiesterase Inhibitors Shortens the Duration of Tuberculosis Treatment

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Microbiology

Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis

Ian M. Rosenthal et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)

Review Pharmacology & Pharmacy

PDE4: A Novel Target in the Treatment of Chronic Obstructive Pulmonary Disease

J. M. Michalski et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)

Article Immunology

Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor

Miki Kobayashi et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2012)

Article Microbiology

Sterilizing Activity of Novel TMC207-and PA-824-Containing Regimens in a Murine Model of Tuberculosis

Rokeya Tasneen et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)

Review Pharmacology & Pharmacy

Targeting cancer with phosphodiesterase inhibitors

Rajkumar Savai et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)

Article Medicine, General & Internal

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

Ian M. Rosenthal et al.

PLOS MEDICINE (2007)

Review Cardiac & Cardiovascular Systems

Overview of PDEs and their regulation

Kenji Omori et al.

CIRCULATION RESEARCH (2007)

Article Respiratory System

Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice

O. Leclerc et al.

EUROPEAN RESPIRATORY JOURNAL (2006)